Navigation Links
CryoLife's Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Date:10/30/2008

hesis, which is CE marked for distribution within the European Community.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated 2008 and 2009 performance. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the Company is significantly dependent on revenues from BioGlue and there are a variety of risks affecting BioGlue, the possibility that the FDA could impose additional restrictions on the Company's operations, issue a 483, or warning letter, or require a recall, or prevent the Company from processing and distributing tissues or manufacturing and distributing other products, demand for CryoValve SG may not reach anticipated levels, CryoValve SG may not perform as well as expected or provide all the benefits anticipated, SynerGraft processed heart valves have a one year shelf life, competitive pressures and tissue availability may adversely affect the Company's ability to grow revenues, the SynerGraft post-clearance study requested by the FDA may not provide the expected positive results, our products and tissues we process and preserve have allegedly caused and may in the future cause injury to patients, the Company's key growth strategies identified as a result of our strategic review may not generate the anticipated benefits, our ability to borrow under our credit facility may be limited, the credit facility limits our ability to pursue significant acquisitions, the financial and credit liquidity crisis may adversely affect our ability to borrow money or raise capital, there are limitations on our use of net operating loss carry-forwards, adverse regulatory action outside of the Uni
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
2. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
3. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
4. Life on Mars pregnancy test successfully launched
5. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. Nikon Instruments Launches New Eclipse Ti-E Fully-Integrated, Motorized Inverted Microscope
8. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series
11. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 01, 2015 Spirax Sarco, the leader ... proud to announce that for the first time in ... winner of a Queen’s Award for Innovation – the ... and manufacture of a unique flowmeter. , The Spirax ... to traditional steam flow measurement. The device provides ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics including high ... the closing of its previously announced underwritten public ... at a public offering price of $15.50 per ... the underwriters of their option to purchase up ...
(Date:4/30/2015)... April 30, 2015 Available in ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative ... reactive skin while battling the weakening threat of ... cream is formulated with star ingredient GLYCOSEA, a ... in a complex of soothing minerals and trace ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3
... 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Paul Bisaro, Watson,s President and Chief Executive Officer, will ... at the Goldman Sachs Global Healthcare Conference 2012 on ... the Terranea Resort in Rancho Palos Verdes, California.  The ...
... 2012 TOKU-E Company ( http://www.toku-e.com ) ... faster dissolving dust-free grade (DF) Sodium Dodecyl Sulfate (SDS). ... dust particles is known to cause eye and skin ... chronic skin hypersensitivity, with some people being affected more ...
... SEATTLE, May 29, 2012 Cell Therapeutics, Inc. ("CTI") (Nasdaq ... an agreement to sell, subject to customary closing conditions, $40 ... and warrants to purchase shares of its common stock (and ... upon conversion of the Series 15 Convertible Preferred Stock and ...
Cached Biology Technology:Watson to Present at Goldman Sachs Global Healthcare Conference 2012 2TOKU-E Announces Safer and Faster Dissolving, Dust-Free Grade Sodium Dodecyl Sulfate (SDS) for Electrophoresis and Manufacturing Applications 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 2Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 3Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 4Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 5Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock 6
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... fictitious storybook character Dr. Doolittle was known for ... professor of psychology at Rochester Institute of Technology, ... object discrimination in goldfish and echolocation in dolphins ... of animal perception and cognition. DeLong,s theories ...
... California, Davis, and BGI, the world,s largest genomic institute, ... will change the landscape of genomic sciences in California ... the areas of food security and human, animal and ... BGI sequencing facility for immediate use on the UC ...
... CAMDEN -- In this era of environmental consciousness, many ... is taking the term quite literally. Elizabeth Demaray, an ... sides of New York City skyscrapers to counteract the lack ... Skyscrapers Project" was featured as part of New York,s Art ...
Cached Biology News:Go fish! RIT psychology professor trains goldfish for object perception research 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... TYPE II Reacts with most of ... cell keratin of 86 and 58kD and ... keratin reactivity is found on human epidermal ... Immunogen: Human epidermal cells ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Biology Products: